Please login to the form below
Arcus Biosciences
This page shows the latest Arcus Biosciences news and features for those working in and with pharma, biotech and healthcare.
Gilead to pay $745m for three oncology programmes from Arcus Biosciences
The deal will enable Gilead to accelerate the development of candidate molecules and explore treatment combinations with long-term partner Arcus Biosciences. ... Encouraged by early clinical data, Gilead Sciences is exercising its options on three of
Latest news
-
Gilead agrees $21bn buyout of Immunomedics
In May, Gilead also announced its intent to partner with Arcus Biosciences on the development and commercialisation of next-generation cancer immunotherapies. ... This included gaining rights to zimberelimab, an investigational anti-PD-1 monoclonal
-
Gilead makes a play for novel cancer drug with Tizona deal
That includes a partnership with Arcus Biosciences, agreed in May, for the development and commercialisation of a pipeline of investigational immuno-oncology products.
-
Gilead and Arcus complete closing of ten-year immunotherapy partnership
Deal emphasises Gilead's focus on immuno-oncology. In May, Gilead and Arcus Biosciences announced their intent to partner on the development and commercialisation of next-generation cancer immunotherapies, and have ... Arcus is eligible to receive up to
-
Gilead targets hep B in half a billion dollar deal with Precision BioSciences
This collaboration however, will target the in vivo elimination of the virus and will use Precision BioSciences’ genome editing platform ARCUS to further develop this goal. ... The ARCUS platform is based on a natural genome-editing enzyme homing
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Acquisition. $463m. Precision BioSciences/. Gilead Sciences. ARCUS technology; targeting in vivo elimination of. ... The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome editing platform ARCUS.
-
Pharma deals continue to slide
Arcus, a privately owned US immuno-oncology company, may have to do the same following its deal to license a monoclonal antibody from the Chinese companies WuXi Biologics and Gloria Pharmaceuticals. ... 1, 410 (upfront 80). WuXi Biologics and Gloria
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
